JPMorgan Chase & Co. Grows Holdings in Zura Bio Limited (NASDAQ:ZURA)

JPMorgan Chase & Co. raised its holdings in Zura Bio Limited (NASDAQ:ZURA) by 12,060.8% during the fourth quarter, HoldingsChannel reports. The firm owned 2,633,185 shares of the company’s stock after buying an additional 2,611,532 shares during the period. JPMorgan Chase & Co.’s holdings in Zura Bio were worth $6,583,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. American Century Companies Inc. acquired a new stake in shares of Zura Bio in the 4th quarter worth $27,000. Prudential Financial Inc. acquired a new position in Zura Bio during the 4th quarter worth approximately $28,000. SG Americas Securities LLC raised its stake in shares of Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after buying an additional 7,828 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Zura Bio by 37.3% in the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock valued at $94,000 after buying an additional 10,231 shares during the period. Finally, Barclays PLC boosted its stake in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after buying an additional 56,757 shares in the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Stock Up 7.0 %

NASDAQ ZURA opened at $1.23 on Friday. Zura Bio Limited has a fifty-two week low of $0.97 and a fifty-two week high of $6.35. The business has a fifty day moving average of $1.28 and a 200-day moving average of $2.44. The stock has a market cap of $84.10 million, a price-to-earnings ratio of -2.32 and a beta of 0.08.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. As a group, analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ZURA. Chardan Capital reduced their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Guggenheim reaffirmed a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Oppenheimer reissued an “outperform” rating and set a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zura Bio has a consensus rating of “Buy” and an average price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.